美国FDA批准武田制药与Protagonist公司联合研发的罕见血液癌症药物

路透中文
Aug 29
美国FDA批准<a href="https://laohu8.com/S/TAK">武田制药</a>与Protagonist公司联合研发的罕见血液癌症药物

路透8月28日 - 美国食品和药物管理局(FDA)周五表示,已批准武田制药(4502.T)与Protagonist Therapeutics(PTGX.O)联合研发的首款用于治疗一种罕见血液癌症的药物。

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10